Cancer Family
Lymphocytic Neoplasm
CI-CAN-00000223Explore in graph →
HematologicNon-malignant3,036 active trials72 approved drugs345 evidence items
- NCIt
- C7065
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000223Explore in graph →
Clinical trials
12,949 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01313611 | BRIEF Bendamustine and Rituximab In Elderly Follicular(BRIEF) | terminated | Phase 2 | 62 | The Lymphoma Academic Research OrganisationOTHER | 2 | Mar 7, 2018 | clinicaltrials |
| NCT02419755 | Bortezomib and Vorinostat in Younger Patients With Refractory or Relapsed MLL Rearranged Hematologic Malignancies | terminated | Phase 2 | 12 | St. Jude Children's Research HospitalOTHER | 1 | Mar 7, 2018 |
| clinicaltrials |
| NCT00478062 | Vaccine Therapy in Treating Patients Who Have Received First-Line Therapy for Hodgkin's Lymphoma | terminated | Phase 1 / Phase 2 | 1 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Feb 28, 2018 | clinicaltrials |
| NCT01147393 | Combination Veltuzumab and Fractionated 90Y- Epratuzumab Radioimmunotherapy in Follicular Lymphoma | terminated | Phase 1 / Phase 2 | 4 | Weill Medical College of Cornell UniversityOTHER | 1 | Feb 22, 2018 | clinicaltrials |
| NCT01685021 | Study of Fc-Optimized Anti-CD19 Antibody (MOR00208) to Treat B-cell Acute Lymphoblastic Leukemia(B-ALL) | terminated | Phase 2 | 22 | MorphoSys AGINDUSTRY | 1 | Feb 22, 2018 | clinicaltrials |
| NCT00481832 | Autologous Followed by Non-myeloablative Allogeneic Transplantation for Non-Hodgkin's Lymphoma | terminated | Phase 2 | 50 | Stanford UniversityOTHER | 1 | Feb 14, 2018 | clinicaltrials |
| NCT01315873 | Bortezomib and Bendamustine to Treat Relapsed/Refractory Myeloma | terminated | Phase 2 | 24 | NYU Langone HealthOTHER | 1 | Feb 7, 2018 | clinicaltrials |
| NCT00003500 | Antineoplaston Therapy in Treating Patients With Intermediate-Grade Stage II - IV Non-Hodgkin's Lymphoma | terminated | Phase 2 | 12 | Burzynski Research InstituteOTHER | 1 | Feb 5, 2018 | clinicaltrials |
| NCT00003501 | Antineoplaston Therapy in Treating Patients With High-Grade Stage II - Stage IV Non-Hodgkin's Lymphoma | terminated | Phase 2 | 2 | Burzynski Research InstituteOTHER | 1 | Feb 5, 2018 | clinicaltrials |
| NCT01675141 | Lenalidomide Maintenance Therapy for Multiple Myeloma | terminated | Phase 2 | 11 | National Cancer Institute (NCI)NIH | 1 | Feb 5, 2018 | clinicaltrials |
| NCT01446900 | R-2cda and Prolongation of Therapy With Rituximab Alone in Chronic Lymphocytic Leukaemia and Small Lymphocytic Lymphoma | terminated | Phase 2 | 25 | European Institute of OncologyOTHER | 1 | Jan 31, 2018 | clinicaltrials |
| NCT02983097 | Therapy of Non-Hodgkin-Lymphoma by Combination of Lenalidomide + Rituximab, Dexa, High-dose ARA-C and CisP(R²-DHAP) | terminated | Phase 1 / Phase 2 | 34 | Gesellschaft fur Medizinische Innovation - Hamatologie und Onkologie mbHOTHER | 1 | Jan 19, 2018 | clinicaltrials |
| NCT00455897 | CHOP-Rituximab Augmented With GM-CSF in Patients With Previously Untreated Diffuse Large B Cell Non-Hodgkin's Lymphoma | terminated | Phase 2 | 3 | Massachusetts General HospitalOTHER | 1 | Jan 18, 2018 | clinicaltrials |
| NCT02456675 | INCB040093 and INCB040093 Combined With Itacitinib (INCB039110) in Relapsed/Refractory Hodgkin Lymphoma | terminated | Phase 2 | 8 | Incyte CorporationINDUSTRY | 0 | Jan 12, 2018 | clinicaltrials |
| NCT01564277 | Rasburicase and Allopurinol in Treating Patients With Hematologic Malignancies | terminated | Phase 2 | 24 | Roswell Park Cancer InstituteOTHER | 1 | Jan 9, 2018 | clinicaltrials |
| NCT00295880 | Donor Umbilical Cord Blood Transplant By Injection Into the Bone Marrow in Treating Patients With Hematologic Cancer | terminated | Phase 1 / Phase 2 | 12 | Masonic Cancer Center, University of MinnesotaOTHER | 0 | Dec 28, 2017 | clinicaltrials |
| NCT00602446 | Deferasirox in Treating Patients With Iron Overload After Undergoing a Donor Stem Cell Transplant | terminated | Phase 2 | 4 | Masonic Cancer Center, University of MinnesotaOTHER | 1 | Dec 28, 2017 | clinicaltrials |
| NCT00625729 | Donor Natural Killer Cell Infusion, Rituximab, Aldesleukin, and Chemotherapy in Treating Patients With Relapsed Non-Hodgkin Lymphoma or Chronic Lymphocytic Leukemia | terminated | Phase 1 / Phase 2 | 6 | Masonic Cancer Center, University of MinnesotaOTHER | 1 | Dec 28, 2017 | clinicaltrials |
| NCT00882206 | Pre-reinductive Decitabine and Vorinostat in Relapsed Lymphoblastic Lymphoma or Acute Lymphoblastic Leukemia | terminated | Phase 2 | 15 | Masonic Cancer Center, University of MinnesotaOTHER | 1 | Dec 28, 2017 | clinicaltrials |
| NCT00963872 | Donor Umbilical Cord Blood Transplant After Fludarabine Phosphate, Cyclophosphamide, and Total-Body Irradiation in Treating Patients With High-Risk Hematologic Cancer | terminated | Phase 1 / Phase 2 | 31 | Masonic Cancer Center, University of MinnesotaOTHER | 1 | Dec 28, 2017 | clinicaltrials |
| NCT01312818 | Bortezomib, Vorinostat and Dexamethasone for Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL) | terminated | Phase 2 | 2 | Masonic Cancer Center, University of MinnesotaOTHER | 1 | Dec 28, 2017 | clinicaltrials |
| NCT01636388 | Allogeneic Stem Cell Transplantation With Adoptive Immunotherapy in Epstein-Barr Virus Positive Recurrent/Refractory Hodgkins Lymphoma | terminated | Phase 2 | 2 | New York Medical CollegeOTHER | 1 | Dec 22, 2017 | clinicaltrials |
| NCT01343368 | Preservation of Ovarian Function After Hematopoietic Cell Transplant | terminated | Phase 2 | 19 | Masonic Cancer Center, University of MinnesotaOTHER | 1 | Dec 5, 2017 | clinicaltrials |
| NCT01518465 | Dalteparin, Lenalidomide, and Low-Dose Dexamethasone in Treating Patients With Previously Untreated Multiple Myeloma | terminated | Phase 2 | 13 | University of Southern CaliforniaOTHER | 1 | Nov 29, 2017 | clinicaltrials |
| NCT01969565 | Study of Carfilzomib in Combination w/Dexamethasone in Patients w/Newly Diagnosed Multiple Myeloma | terminated | Phase 2 | 1 | Emory UniversityOTHER | 1 | Nov 24, 2017 | clinicaltrials |
| NCT00110149 | Rituximab and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Non-Hodgkin's Lymphoma | terminated | Phase 2 | 12 | Beth Israel Deaconess Medical CenterOTHER | 1 | Nov 21, 2017 | clinicaltrials |
| NCT01187446 | Low-dose (12 Gy) TSEBT+Vorinostat Versus Low-dose TSEBT Monotherapy in Mycosis Fungoides | terminated | Phase 1 / Phase 2 | 28 | Stanford UniversityOTHER | 1 | Nov 20, 2017 | clinicaltrials |
| NCT02815397 | DA-EPOCH-Rituximab/Metformin (RM) for Double Hit Lymphoma(DLBCL) | terminated | Phase 2 | 2 | Rush University Medical CenterOTHER | 1 | Nov 17, 2017 | clinicaltrials |
| NCT00722865 | Avastin (Bevacizumab) Plus Adriamycin, Bleomycin, Vinblastine and Dacarbazine (ABVD) for Advanced Stage Hodgkin Lymphoma | terminated | Phase 2 | 25 | Massachusetts General HospitalOTHER | 1 | Oct 18, 2017 | clinicaltrials |
| NCT00113919 | UARK 2003-25: A Study of Intravenous (IV) Busulfan (Busulfex®) in Multiple Myeloma Patients | terminated | Phase 1 / Phase 2 | 14 | University of ArkansasOTHER | 1 | Oct 16, 2017 | clinicaltrials |
| NCT01646762 | Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Relapsed or Refractory Multiple Myeloma | terminated | Phase 2 | 13 | Mayo ClinicOTHER | 1 | Oct 16, 2017 | clinicaltrials |
| NCT02455297 | Phase IIa Study of Copanlisib in Relapsed or Refractory Mantle Cell Lymphoma (MCL) | terminated | Phase 2 | 4 | BayerINDUSTRY | 1 | Oct 2, 2017 | clinicaltrials |
| NCT00281879 | Donor Stem Cell Transplant or Donor White Blood Cell Infusions in Treating Patients With Hematologic Cancer | terminated | Phase 2 | 200 | OHSU Knight Cancer InstituteOTHER | 1 | Sep 27, 2017 | clinicaltrials |
| NCT00849251 | Pegylated Liposomal Doxorubicin Hydrochloride, Bortezomib, Cyclophosphamide, and Dexamethasone in Treating Patients With Multiple Myeloma | terminated | Phase 1 / Phase 2 | 31 | University of WashingtonOTHER | 1 | Sep 8, 2017 | clinicaltrials |
| NCT00857324 | Study of Vorinostat Plus Melphalan and Prednisone (Zmp) in Advanced, Refractory Multiple Myeloma Patients | terminated | Phase 1 / Phase 2 | 18 | Tiziana MarangonOTHER | 1 | Sep 6, 2017 | clinicaltrials |
| NCT01720043 | Hemostatic Effects of VELCADE®* Treatment in Multiple Myeloma Patients | terminated | Phase 2 | 8 | University of UtahOTHER | 1 | Sep 5, 2017 | clinicaltrials |
| NCT01383447 | Entinostat And Imatinib Mesylate In Treating Patients With Relapsed or Refractory Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia | terminated | Phase 1 / Phase 2 | 2 | National Cancer Institute (NCI)NIH | 1 | Aug 8, 2017 | clinicaltrials |
| NCT00714259 | Non-Myeloablative Allogeneic HSCT From HLA Matched Related or Unrelated Donors for the Treatment of Low Grade B Cell Malignancies | terminated | Phase 2 / Phase 3 | 5 | University of Alabama at BirminghamOTHER | 1 | Jul 24, 2017 | clinicaltrials |
| NCT00837200 | Oncaspar/Doxil/Decadron in Patients With Refractory Lymphoid Malignancies | terminated | Phase 2 | 13 | Milton S. Hershey Medical CenterOTHER | 1 | Jul 24, 2017 | clinicaltrials |
| NCT00843310 | Combination of Revlimid, Melphalan and Dexamethasone as First Line Treatment for Multiple Myeloma | terminated | Phase 2 | 8 | NYU Langone HealthOTHER | 1 | Jul 19, 2017 | clinicaltrials |
| NCT00496132 | A Trial of the Safety of Escalating Doses of PRO131921 in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia | terminated | Phase 1 / Phase 2 | 16 | Genentech, Inc.INDUSTRY | 0 | Jul 2, 2017 | clinicaltrials |
| NCT00450385 | Genes in Predicting Outcome of Patients With DLBCL Treated With Rituximab and Combination Chemotherapy (R-CHOP)(R-CHOP) | terminated | Phase 2 | 57 | University of MiamiOTHER | 1 | Jun 23, 2017 | clinicaltrials |
| NCT00719849 | Donor Umbilical Cord Blood Transplant in Treating Patients With Advanced Hematological Cancer or Other Disease | terminated | Phase 2 | 13 | Fred Hutchinson Cancer CenterOTHER | 1 | Jun 14, 2017 | clinicaltrials |
| NCT01548573 | Tandem Auto Transplantation in Myeloma Patients With <12 Months of Prior Treatment | terminated | Phase 2 | 19 | University of IowaOTHER | 1 | Jun 14, 2017 | clinicaltrials |
| NCT01965834 | Phase II Study to Evaluate Fenofibrate Therapy in Patients With Smoldering or Symptomatic Multiple Myeloma | terminated | Phase 2 | 6 | University of MiamiOTHER | 1 | Jun 14, 2017 | clinicaltrials |
| NCT02619812 | Manage Diarrhea in Patients With Multiple Myeloma While Receiving Conditioning Chemotherapy for Autologous SCT | terminated | Phase 2 | 4 | Mayo ClinicOTHER | 1 | Jun 14, 2017 | clinicaltrials |
| NCT01220297 | Sirolimus & Mycophenolate Mofetil as GvHD Prophylaxis in Myeloablative, Matched Related Donor HCT | terminated | Phase 2 | 3 | Stanford UniversityOTHER | 1 | Jun 5, 2017 | clinicaltrials |
| NCT00676806 | A Phase II Study of Umbilical Cord Blood Transplantation | terminated | Phase 2 | 7 | Tufts Medical CenterOTHER | 1 | Jun 1, 2017 | clinicaltrials |
| NCT01729338 | Velcade + Cyclophosphamide in Newly Diagnosed Multiple Myeloma | terminated | Phase 2 | 17 | Duke UniversityOTHER | 1 | May 31, 2017 | clinicaltrials |
Data updated 23 days agoSource updated Mar 7, 2018source: clinicaltrials